Current Strategies to Enhance Delivery of Drugs across the Blood-Brain Barrier.
| Title: | Current Strategies to Enhance Delivery of Drugs across the Blood-Brain Barrier. |
|---|---|
| Authors: | Teleanu RI; Department of Pediatric Neurology, 'Dr. Victor Gomoiu' Children's Hospital, 022102 Bucharest, Romania.; 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.; Preda MD; Department of Science and Engineering of Oxide Materials and Nanomaterials, Faculty of Applied Chemistry and Materials Science, Politehnica University of Bucharest, 011061 Bucharest, Romania.; Niculescu AG; Department of Science and Engineering of Oxide Materials and Nanomaterials, Faculty of Applied Chemistry and Materials Science, Politehnica University of Bucharest, 011061 Bucharest, Romania.; Vladâcenco O; Department of Pediatric Neurology, 'Dr. Victor Gomoiu' Children's Hospital, 022102 Bucharest, Romania.; 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.; Radu CI; Department of Neurosurgery (I), Bucharest University Emergency Hospital, 050098 Bucharest, Romania.; Grumezescu AM; Department of Science and Engineering of Oxide Materials and Nanomaterials, Faculty of Applied Chemistry and Materials Science, Politehnica University of Bucharest, 011061 Bucharest, Romania.; Research Institute of the University of Bucharest-ICUB, University of Bucharest, 050657 Bucharest, Romania.; Academy of Romanian Scientists, Ilfov No. 3, 050044 Bucharest, Romania.; Teleanu DM; 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania. |
| Source: | Pharmaceutics [Pharmaceutics] 2022 May 04; Vol. 14 (5). Date of Electronic Publication: 2022 May 04. |
| Publication Type: | Journal Article; Review |
| Language: | English |
| Journal Info: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101534003 Publication Model: Electronic Cited Medium: Print ISSN: 1999-4923 (Print) Linking ISSN: 19994923 NLM ISO Abbreviation: Pharmaceutics Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: Basel, Switzerland : MDPI |
| Abstract: | The blood-brain barrier (BBB) has shown to be a significant obstacle to brain medication delivery. The BBB in a healthy brain is a diffusion barrier that prevents most substances from passing from the blood to the brain; only tiny molecules can pass across the BBB. The BBB is disturbed in specific pathological illnesses such as stroke, diabetes, seizures, multiple sclerosis, Parkinson's disease, and Alzheimer's disease. The goal of this study is to offer a general overview of current brain medication delivery techniques and associated topics from the last five years. It is anticipated that this review will stimulate readers to look into new ways to deliver medications to the brain. Following an introduction of the construction and function of the BBB in both healthy and pathological conditions, this review revisits certain contested questions, such as whether nanoparticles may cross the BBB on their own and if medications are selectively delivered to the brain by deliberately targeted nanoparticles. Current non-nanoparticle options are also discussed, including drug delivery via the permeable BBB under pathological circumstances and the use of non-invasive approaches to improve brain medication absorption. |
| References: | Proteins. 2001 May 1;43(2):89-102. (PMID: 11276079); J Neurosci. 2016 Dec 7;36(49):12296-12298. (PMID: 27927949); Proc Natl Acad Sci U S A. 2017 Jan 24;114(4):E524-E533. (PMID: 28069965); Chemosphere. 2021 Jun;273:129579. (PMID: 33493816); Expert Opin Pharmacother. 2008 Feb;9(2):301-9. (PMID: 18201152); Mol Interv. 2003 Mar;3(2):90-105, 51. (PMID: 14993430); Trends Pharmacol Sci. 1996 Oct;17(10):364-72. (PMID: 8979771); J Control Release. 2019 Aug 10;307:247-260. (PMID: 31252036); Bioconjug Chem. 2014 Oct 15;25(10):1777-84. (PMID: 25220352); Adv Sci (Weinh). 2019 Dec 23;7(3):1902583. (PMID: 32042569); Curr Biol. 2018 Apr 23;28(8):R435-R444. (PMID: 29689228); Drug Metab Dispos. 2020 Nov;48(11):1183-1190. (PMID: 32862147); Lab Invest. 2000 Jun;80(6):973-80. (PMID: 10879747); Expert Opin Ther Pat. 2020 Mar;30(3):179-194. (PMID: 32003260); Rev Neurosci. 2019 Jul 26;30(5):555-572. (PMID: 30753166); Biomolecules. 2021 Apr 24;11(5):. (PMID: 33923147); Curr Pharm Biotechnol. 2011 Jun;12(6):946-55. (PMID: 21506913); Magn Reson Imaging. 2017 Apr;37:273-281. (PMID: 27916657); Front Neurosci. 2017 Feb 23;11:86. (PMID: 28280455); Expert Opin Ther Targets. 2017 May;21(5):511-530. (PMID: 28335655); J Control Release. 2018 May 10;277:89-101. (PMID: 29522834); RSC Adv. 2017;7(68):42811-42818. (PMID: 29308191); Chem Rev. 2015 Oct 14;115(19):10938-66. (PMID: 26010257); J Investig Med. 2012 Dec;60(8):1131-40. (PMID: 23138008); BMC Neurosci. 2008 Dec 10;9 Suppl 3:S5. (PMID: 19091002); Pharmaceutics. 2021 Aug 12;13(8):. (PMID: 34452206); Sci Rep. 2020 Oct 26;10(1):18220. (PMID: 33106562); J Cell Mol Med. 2018 Sep;22(9):4171-4182. (PMID: 29956460); AAPS J. 2017 Mar;19(2):475-486. (PMID: 27882487); Mol Divers. 2017 May;21(2):355-365. (PMID: 28050687); Nature. 1997 Aug 14;388(6643):674-8. (PMID: 9262401); J Extracell Vesicles. 2015 Apr 20;4:26316. (PMID: 25899407); Drug Deliv. 2018 Nov;25(1):472-483. (PMID: 29412012); Lancet Infect Dis. 2013 Jul;13(7):629-37. (PMID: 23735626); Acta Neuropathol. 2011 Jul;122(1):1-9. (PMID: 21656168); J Cell Physiol. 2019 Jun;234(6):8249-8258. (PMID: 30378105); Endocrinology. 2004 Aug;145(8):3935-40. (PMID: 15131016); Ultrasound Med Biol. 2012 Aug;38(8):1372-82. (PMID: 22579546); J Control Release. 2016 Feb 28;224:77-85. (PMID: 26773767); Int J Nanomedicine. 2018 Sep 20;13:5561-5576. (PMID: 30271147); Sci Rep. 2016 Feb 25;6:21933. (PMID: 26911358); Nat Rev Drug Discov. 2021 May;20(5):362-383. (PMID: 33649582); ACS Comb Sci. 2017 Feb 13;19(2):55-80. (PMID: 28045249); Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12432-7. (PMID: 12205295); ACS Chem Neurosci. 2018 Mar 21;9(3):395-397. (PMID: 29431424); Mol Cell Neurosci. 2016 Dec;77:76-86. (PMID: 27989734); Neuron. 2008 Jan 24;57(2):178-201. (PMID: 18215617); Proc Natl Acad Sci U S A. 1995 Oct 10;92(21):9829-33. (PMID: 7568227); Mol Ther. 2003 Dec;8(6):911-7. (PMID: 14664793); J Mater Chem B. 2017 Sep 21;5(35):7216-7237. (PMID: 32264173); Theranostics. 2020 Jan 1;10(4):1604-1618. (PMID: 32042325); ACS Chem Biol. 2016 Oct 21;11(10):2812-2819. (PMID: 27513597); Ann Indian Acad Neurol. 2017 Jul-Sep;20(3):185-189. (PMID: 28904446); J Am Chem Soc. 2003 May 14;125(19):5823-31. (PMID: 12733923); FEBS Lett. 2020 Dec;594(23):3799-3814. (PMID: 33098660); Theranostics. 2020 Jun 12;10(16):7422-7435. (PMID: 32642003); J Stroke Cerebrovasc Dis. 2004 Jan-Feb;13(1):16-23. (PMID: 17903945); Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3811-6. (PMID: 15728733); J Immunol. 2017 Nov 15;199(10):3559-3570. (PMID: 28978688); Int J Nanomedicine. 2019 Oct 21;14:8321-8344. (PMID: 31695370); Expert Opin Drug Deliv. 2017 Jun;14(6):811-824. (PMID: 27690671); Pharmaceutics. 2017 Mar 27;9(2):. (PMID: 28346375); Bioelectrochemistry. 2014 Oct;99:30-9. (PMID: 24976141); N Engl J Med. 2001 Jan 18;344(3):182-8. (PMID: 11172140); Theranostics. 2018 Feb 5;8(6):1481-1493. (PMID: 29556336); Curr Drug Deliv. 2019;16(8):698-711. (PMID: 31456519); Cancer Drug Resist. 2021;4:620-633. (PMID: 34308273); Acta Biomater. 2017 Jan 1;47:182-192. (PMID: 27721007); Neuroscience. 2004;127(2):481-96. (PMID: 15262337); Int Rev Neurobiol. 2020;151:1-66. (PMID: 32448602); CNS Drugs. 2017 Feb;31(2):109-133. (PMID: 28101766); J Cereb Blood Flow Metab. 2021 Jul;41(7):1634-1646. (PMID: 33081568); Nat Rev Neurosci. 2006 Jan;7(1):41-53. (PMID: 16371949); Cells. 2020 Mar 24;9(3):. (PMID: 32213945); J Control Release. 2009 May 21;136(1):14-20. (PMID: 19331861); J Pharmacol Exp Ther. 2003 Oct;307(1):182-9. (PMID: 12954805); Neuropharmacology. 2017 Jul 1;120:4-7. (PMID: 27561970); JIMD Rep. 2019;43:91-101. (PMID: 29923090); Int J Pharm. 2021 Apr 15;599:120351. (PMID: 33545286); Neurobiol Dis. 2004 Jun;16(1):1-13. (PMID: 15207256); Exp Neurol. 2016 Apr;278:11-21. (PMID: 26626972); Pharm Res. 2009 Nov;26(11):2486-94. (PMID: 19774344); Gene Ther. 2009 Nov;16(11):1340-52. (PMID: 19587708); Adv Drug Deliv Rev. 1995 Jul;15(1-3):5-36. (PMID: 35524389); Pharmacol Rev. 2003 Sep;55(3):425-61. (PMID: 12869659); Lancet Neurol. 2008 Jan;7(1):84-96. (PMID: 18093565); JACC Basic Transl Sci. 2019 Nov 25;4(7):845-854. (PMID: 31998852); Front Neurosci. 2019 Jan 11;12:1019. (PMID: 30686985); J Exp Med. 2020 Apr 6;217(4):. (PMID: 32211826); Biochim Biophys Acta Gen Subj. 2017 Jun;1861(6):1515-1520. (PMID: 28017683); Nanomaterials (Basel). 2019 Apr 03;9(4):. (PMID: 30987211); J Prev Alzheimers Dis. 2014 Mar;1(3):138-139. (PMID: 26301207); Pharmaceutics. 2021 Oct 26;13(11):. (PMID: 34834200); Drug Resist Updat. 2015 Mar;19:1-12. (PMID: 25791797); Front Oncol. 2020 Nov 16;10:561936. (PMID: 33312947); PLoS One. 2012;7(9):e45992. (PMID: 23049915); Biochim Biophys Acta Mol Basis Dis. 2019 Mar 1;1865(3):634-647. (PMID: 30611861); Int J Mol Sci. 2021 Apr 03;22(7):. (PMID: 33916769); Nat Methods. 2010 Nov;7(11):905-7. (PMID: 20953176); J Control Release. 2020 Oct 10;326:599-614. (PMID: 32730952); Sci Rep. 2016 Mar 04;6:22595. (PMID: 26940762); Sci Rep. 2017 Jan 24;7:41316. (PMID: 28117381); Int J Cancer. 2016 Jan 1;138(1):14-21. (PMID: 25559768); Eur J Drug Metab Pharmacokinet. 2017 Dec;42(6):915-933. (PMID: 28374336); J Control Release. 2017 Mar 28;250:77-85. (PMID: 27742444); Addict Biol. 2020 Jan;25(1):e12683. (PMID: 30334599); Nature. 2005 Feb 10;433(7026):561. (PMID: 15703711); J Control Release. 2017 May 10;253:165-171. (PMID: 28322975); Life Sci. 2021 Apr 1;270:119142. (PMID: 33524419); Nanomaterials (Basel). 2018 Mar 20;8(3):. (PMID: 29558440); Int J Mol Sci. 2018 Dec 02;19(12):. (PMID: 30513816); Pharm Res. 2013 Oct;30(10):2499-511. (PMID: 23959851); Nat Nanotechnol. 2021 Mar;16(3):266-276. (PMID: 33712737); Nanomedicine (Lond). 2016 Apr;11(7):833-49. (PMID: 26980585); J Neural Eng. 2010 Feb;7(1):16005. (PMID: 20075507); Neurology. 2017 Jan 31;88(5):433-440. (PMID: 28031392); Int J Nanomedicine. 2016 Oct 18;11:5381-5414. (PMID: 27799765); J Liposome Res. 2020 Dec;30(4):336-365. (PMID: 31558079); Front Neurol. 2018 May 14;9:328. (PMID: 29867737); Circ Res. 2017 Jan 6;120(1):179-206. (PMID: 28057793); Int J Nanomedicine. 2015 Aug 04;10:4981-5003. (PMID: 26345528); Nanomaterials (Basel). 2019 Mar 22;9(3):. (PMID: 30909401); Genet Med. 2016 Jan;18(1):73-81. (PMID: 25834948); Trends Endocrinol Metab. 2004 Sep;15(7):300-10. (PMID: 15350601); J Pharmacol Exp Ther. 2004 Oct;311(1):290-7. (PMID: 15166257); Am J Physiol Lung Cell Mol Physiol. 2000 Dec;279(6):L1218-25. (PMID: 11076812); Curr Pharm Des. 2017;23(40):6206-6214. (PMID: 28914201); BMC Neurol. 2009 Jun 12;9 Suppl 1:S3. (PMID: 19534732); Sci Rep. 2016 May 16;6:25794. (PMID: 27180729); J Transl Med. 2009 Sep 01;7:77. (PMID: 19723323); Annu Rev Biochem. 2020 Jun 20;89:605-636. (PMID: 32569521); Ann Neurol. 2003 Mar;53(3):405-9. (PMID: 12601711); Expert Rev Neurother. 2008 Jan;8(1):9-17. (PMID: 18088197); Bioconjug Chem. 2017 Jan 18;28(1):153-160. (PMID: 27537821); Histol Histopathol. 2018 Jan;33(1):1-10. (PMID: 28540715); Nat Rev Drug Discov. 2016 Apr;15(4):275-92. (PMID: 26794270); Pharmaceutics. 2019 Dec 23;12(1):. (PMID: 31878061); Neuroreport. 2020 Apr 8;31(6):466-472. (PMID: 32168101); Front Pharmacol. 2012 Apr 30;3:74. (PMID: 22557971); Pflugers Arch. 2020 Sep;472(9):1299-1343. (PMID: 32789766); ACS Chem Neurosci. 2020 Jul 1;11(13):1985-1995. (PMID: 32464055); Best Pract Res Clin Endocrinol Metab. 2015 Mar;29(2):159-71. (PMID: 25987170); Pharmacol Rev. 2011 Mar;63(1):1-34. (PMID: 21303899); Int Immunopharmacol. 2019 Feb;67:268-280. (PMID: 30572251); Naunyn Schmiedebergs Arch Pharmacol. 2021 Aug;394(8):1737-1755. (PMID: 34086100); Drug Discov Today Technol. 2016 Jun;20:41-48. (PMID: 27986222); J Nanosci Nanotechnol. 2004 May;4(5):484-8. (PMID: 15503433); Fluids Barriers CNS. 2015 Sep 02;12:20. (PMID: 26330053); Ultrasound Med Biol. 2008 Jul;34(7):1093-104. (PMID: 18378064); Fluids Barriers CNS. 2020 Nov 18;17(1):69. (PMID: 33208141); Sci Rep. 2017 Jan 13;7:40358. (PMID: 28084426); Front Cell Neurosci. 2018 Nov 26;12:459. (PMID: 30534057); Br J Clin Pharmacol. 2017 Sep;83(9):1991-1999. (PMID: 28401570); Fluids Barriers CNS. 2020 Jul 22;17(1):47. (PMID: 32698806); NeuroRx. 2005 Jan;2(1):44-53. (PMID: 15717056); Colloids Surf B Biointerfaces. 2018 Jan 1;161:302-313. (PMID: 29096375); Drug Discov Today. 2021 Aug;26(8):1944-1952. (PMID: 33865978); Nat Rev Cancer. 2018 Jul;18(7):452-464. (PMID: 29643473); Curr Drug Metab. 2021;22(4):263-279. (PMID: 33305703); Nanomedicine. 2018 Apr;14(3):991-1003. (PMID: 29339188); Expert Opin Drug Deliv. 2014 May;11(5):711-21. (PMID: 24650132); PLoS One. 2012;7(8):e42817. (PMID: 22900052); Neurochem Int. 2018 Oct;119:199-206. (PMID: 29545059); Environ Sci Pollut Res Int. 2022 Feb;29(8):10950-10965. (PMID: 35000160); Drug Deliv. 2019 Dec;26(1):459-469. (PMID: 30957567); Pharmacol Ther. 2014 Nov;144(2):114-22. (PMID: 24854599); Biochem Soc Trans. 2019 Feb 28;47(1):23-36. (PMID: 30626703); ACS Appl Mater Interfaces. 2018 Apr 18;10(15):12341-12350. (PMID: 29564886); PLoS One. 2017 Jan 3;12(1):e0166061. (PMID: 28045902); J Neuroimmunol. 2004 Jun;151(1-2):66-77. (PMID: 15145605); ACS Nano. 2017 Jan 24;11(1):69-83. (PMID: 28068069); Pharmaceutics. 2021 Jan 19;13(1):. (PMID: 33477972); J Control Release. 2019 Sep 10;309:25-36. (PMID: 31326464) |
| Contributed Indexing: | Keywords: blood–brain barrier; medication delivery techniques; nanoparticles |
| Entry Date(s): | Date Created: 20220528 Latest Revision: 20220716 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC9145636 |
| DOI: | 10.3390/pharmaceutics14050987 |
| PMID: | 35631573 |
| Database: | MEDLINE |
Journal Article; Review